Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: A retrospective analysis of 84 patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Chen, Yi Xing ^a   Zeng, Zhao Chong ^a   Tang, Zhao You ^a   Fan, Jia ^a   Zhou, Jian ^a   Jiang, Wei ^a   Zeng, Meng Su ^a   Tan, Yun Shan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN C;

ADULT; ANOREXIA; ARTICLE; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BONE MARROW DISEASE; CACHEXIA; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; JAUNDICE; LIVER FAILURE; LYMPH NODE METASTASIS; MALE; NAUSEA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; VOMITING; BILE DUCT TUMOR; FOLLOW UP; GASTROINTESTINAL TUMOR; INTRAHEPATIC BILE DUCT; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; RADIATION EXPOSURE; TREATMENT OUTCOME;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77956471411     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-492     Document Type: Article

References (30)

1. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 2004, 40:472-477. 10.1016/j.jhep.2003.11.030, 15123362.
2. Ikai I, Itai YJ, Okita K, et al. Report of the 15th follow-up surgery of primary liver cancer. Hepatology Res 2004, 28:21-29.
3. Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001, 193:384-391. 10.1016/S1072-7515(01)01016-X, 11584966.
4. Saxena A, Chua TC, Sarkar A, et al. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg 2010, 14(7):1128-38. 10.1007/s11605-010-1203-1, 20467830.
5. Lang H, Sotiropoulos GC, Sgourakis G, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009, 208(2):218-28. 10.1016/j.jamcollsurg.2008.10.017, 19228533.
6. Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009, 16(11):3048-56. 10.1245/s10434-009-0631-1, 19626372.
7. Fu XH, Tang ZH, Zong M, et al. Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients. Hepatobiliary Pancreat Dis Int 2004, 3:279-283.
8. Hanazaki K, Kajikawa S, Shimozawa N, et al. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology 2002, 49:311-316.
9. Lee MA, Woo IS, Kang JH, et al. Epirubicin, cisplatin, and protracted infusion of 5-Fu (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol 2004, 130:346-350. 10.1007/s00432-003-0534-7, 14997381.
10. Park J, Kim MH, Kim KP, et al. Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver 2009, 3(4):298-305. 10.5009/gnl.2009.3.4.298, 2852727, 20431764.
11. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006, 45:856-867. 10.1016/j.jhep.2006.09.001, 1686172, 17030071.
12. Edge SB. American Joint Committee on Cancer: AJCC cancer staging manual. 2009, New York: Springer, 7.
13. Kawarada Y, Mizumoto R. Diagnosis and treatment of cholangiocellular carcinoma of the liver. Hepatogastroenterology 1990, 37(2):176-81.
14. Zeng ZC, Tang ZY, Fan J, et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients. Cancer J 2006, 14:113-122.
15. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0: An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000, 47:13-47.
16. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol 2009, 69:259-270. 10.1016/j.critrevonc.2008.09.008, 18977670.
17. Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002, 53:969-974.
18. Serafini FM, Sachs D, Bloomston M, et al. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 2001, 67:839-844.
19. Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7:593-600.
20. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008, 13:415-423. 10.1634/theoncologist.2007-0252, 18448556.
21. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study -The UK ABC-01 Study. Br J Cancer 2009, 101(4):621-627. 10.1038/sj.bjc.6605211, 2736816, 19672264.
22. Valle JW, Wasan HS, Palmer DD, et al. Gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer: Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol (Meeting Abstracts) 2009, 27(15S):4503.
23. Malka D, Trarbach T, Fartoux L, et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. J Clin Oncol (Meeting Abstracts) 2009, 27(15S):4520.
24. Herber S, Otto G, Schneider J, et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007, 30:1156-65. 10.1007/s00270-007-9032-7, 17508242.
25. Kim JM, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008, 113:1614-22. 10.1002/cncr.23787, 18704990.
26. Zeng ZC, Tang ZY, Fan J, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004, 10:307-316. 10.1097/00130404-200409000-00008, 15530260.
27. Zeng ZC, Tang ZY, Fan J, et al. Consideration of the role of radiotherapy for lymph node metastases in patients with HCC, retrospective analysis for prognostic factors from 125 patients. Int J Radiation Oncology Biol Phys 2005, 63:1067-1076.
28. Liang SX, Jiang GL, Zhu XD, et al. Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy. Zhonghua Zhong Liu Za Zhi 2005, 27(10):613-5.
29. Mendez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol 2006, 45:831-837. 10.1080/02841860600897934, 16982547.
30. Tse RV, Hawkins M, Lockwood G, et al. Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 2008, 26(4):657-64. 10.1200/JCO.2007.14.3529, 18172187.